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Abstract
Background: The need for rapid and accurate comparison of panels of adjuvanted vaccine formulations and subsequent
rational down selection, presents several challenges for modern vaccine development. Here we describe a method which
may enable vaccine and adjuvant developers to compare antigen/adjuvant combinations in a harmonized fashion. Three
reference antigens: Plasmodium falciparum apical membrane antigen 1 (AMA1), hepatitis B virus surface antigen (HBsAg),
and Mycobacterium tuberculosis antigen 85A (Ag85A), were selected as model antigens and were each formulated with
three adjuvants: aluminium oxyhydroxide, squalene-in-water emulsion, and a liposome formulation mixed with the purified
saponin fraction QS21.
Results: The nine antigen/adjuvant formulations were assessed for stability and immunogenicity in mice in order to
provide benchmarks against which other formulations could be compared, in order to assist subsequent down
selection of adjuvanted vaccines. Furthermore, mouse cellular immune responses were analyzed by measuring IFN-γ
and IL-5 production in splenocytes by ELISPOT, and humoral responses were determined by antigen-specific ELISA,
where levels of total IgG, IgG1, IgG2b and IgG2c in serum samples were determined.
Conclusions: The reference antigens and adjuvants described in this study, which span a spectrum of immune responses,
are of potential use as tools to act as points of reference in vaccine development studies. The harmonized methodology
described herein may be used as a tool for adjuvant/antigen comparison studies.
Keywords: AMA1, Plasmodium falciparum, Hepatitis B, HBsAg, Tuberculosis, Ag85A, Adjuvants, Aluminium oxyhydroxide,
Squalene-in-water SWE, QS21
Background
Despite decades of important advances in vaccine
research and development, effective vaccines for several
infectious diseases, including AIDS/HIV, malaria and
tuberculosis, have not yet reached the population at risk.
Whilst modern antigens based on subunit/recombinant
approaches are often more specific and generally safer,
they also tend to be less immunogenic. Inadequate
immunogenicity is one of the main reasons why vaccine
developers turn to adjuvants, in the hope of improving
levels and quality of the desired immune responses.
At present, the tools openly available that can assist in
making an informed down selection following compari-
son of adjuvants and/or formulations are limited and
not harmonized. Harmonization is important in order to
have consistency when comparing adjuvants and/or for-
mulations in studies. The development of harmonized
assays, including harmonized reagents capable of provid-
ing benchmarking tools by which new adjuvants can be
evaluated and down selected is of clear benefit. Such
tools may also prove to be useful for the comparison of
formulations across studies performed at different times
and places. In order to develop such tools we have
defined and established a set of laboratory assays and re-
agents that can be used as a harmonized benchmarking
tool. This standardized approach will give researchers
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the opportunity to make informed decision when select-
ing specific adjuvants and/or formulations in their stud-
ies (down selection of candidates). These tools were
developed using the following strategy: (i) surveying and
analyzing the current down selection practices used in
global adjuvant R&D, (ii) determining the assays that
were the most appropriate for comparing adjuvant
activities, (iii) disseminating the results and providing
the necessary reagents to interested parties.
A written survey designed to collect information on
adjuvant down selection practices was disseminated at
the Modern Vaccines/Adjuvant Formulation (MVAF)
Conference in Cannes, in October 2010, which was
attended by stakeholders from industry and public
research organizations. The survey was designed to
capture an overview of the methods currently in use in
adjuvant testing. The survey also included a number of
questions on how a harmonized adjuvant evaluation
method could function. The potential techniques identi-
fied in this survey led to the development of the
adjuvant comparison tools described herein.
After analysis of the information collected, an adjuvant
comparison assay was proposed, a set of in vivo experi-
ments designed to evaluate the usefulness of the tool,
and a study performed to investigate if the immune
responses obtained could be used as a benchmark for
other adjuvant comparison studies. As the in vivo
methods which were to be used were critical, as were
the reference materials and assays used in each of the
experiments, it was decided to select three reference
antigens and three reference adjuvants, to be used
together with harmonized protocols in order to evaluate
murine cellular (cytokine: Interferon-γ (IFN-γ) and
interleukin-5 (IL-5) production in splenocytes) and
humoral responses (antibodies: total IgG, IgG1, IgG2b
and IgG2c in sera) induced by each formulation. In mice
IFN-γ skews the antibody response towards the IgG2
isotype, whereas IL-5 skews towards an IgG1 response
[1–3]. Assessment of the cellular and humoral responses
is important to study the efficacy of a vaccine. In cellular
responses T cells are activated which produce different
cytokines. In our study we will study the production of
IL-5, since this cytokine stimulates B cell growth and
increases immunoglobulin secretion, which leads to
higher humoral responses. Furthermore production of
IFN-γ will be studied. This cytokine is critical for innate
and adaptive immunity against viral, some bacterial, and
protozoal infections. It activates macrophages and
induces major histocompatibility complex (MHC) class
II molecule expression in antigen presenting cells, which
are important for initiating immune responses.
In humoral immune responses antibodies are produced
by B cells which cause the destruction of extracellular
microorganisms and prevent the spread of intracellular
infections. In our study total IgG, IgG1, IgG2b and IgG2c
in sera will be studied. IgG2a response in sera will not be
studied, since the study will be conducted in C57BL/6
mice and mice with B6 background lack the Igh-1a allele
that codes for IgG2a [4, 5]. Each of the antigens were
chosen based on availability at GMP quality or as close to
as possible, minimal intellectual property (IP) constraints,
and model for parasitic, viral, and bacterial antigens. The
following antigens were selected: (i) Plasmodium falcip-
arum apical membrane antigen 1 (AMA1), a malaria
vaccine candidate capable of inducing humoral responses
[6, 7], (ii) hepatitis B virus surface antigen (HBsAg), a
particulate viral antigen that induces both cellular and
humoral responses [8], and (iii) Mycobacterium tuberculosis
antigen 85A (Ag85A), a tuberculosis vaccine candidate
eliciting cellular responses [9, 10].
In addition, three reference adjuvants were selected
based on availability at GMP quality or as close to as
possible, distinct immunomodulatory properties, and
distinct type of adjuvant class (delivery system vs. immu-
nomodulator). The following adjuvants were selected: (i)
aluminium oxyhydroxide (AlOH) as the most widely
used class of adjuvant, and which induces mostly Th2-
type skewed immune responses [11], (ii) a squalene-in-
water emulsion (SWE) prepared at the Vaccine Formula-
tion Laboratory, whose composition is similar to MF59™
(Novartis Vaccines and Diagnostics), an adjuvant exten-
sively used in humans as part of seasonal and pandemic
influenza [12], (iii) a liposomal formulation formulated
with the purified saponin QS21 (QS21-Liposomes).
QS21 is an adjuvant currently being tested in various
clinical studies (including cancer, HIV and Alzheimer
vaccines) and is also one component of the AS01
adjuvant system part of the Mosquirix™ malaria vaccine
developed by GlaxoSmithKline Biologicals. QS21 has the
ability to induce both B-cell and T-cell immune
responses in a variety of preclinical models and in
humans [13–15].
Each of the antigens was formulated separately with
each of the adjuvants, resulting in a total of nine
adjuvanted vaccine formulations. Antigens alone were
not included in the in vivo study, as the main aim was
to demonstrate the feasibility of an adjuvanted vaccine
formulation tool.
Methods
Survey
An anonymous questionnaire was designed for research
groups involved in vaccine development in industry and
academia. The questionnaire was introduced to obtain
an overview of the adjuvant testing methods currently in
use in industry and academia. It also included a number
of questions designed to gather information on a harmo-
nized adjuvant evaluation method could be designed.
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Since there is no information in regard to patients’ confi-
dentiality requested in this questionnaire, no ethical
approval is needed (Official Journal of the European
Union, L 119, 4 May 2016 [16]).
Antigens and Adjuvants
AMA1 was produced at cGMP from FVO-strain [17, 18]
and obtained from BPRC. GMP grade HBsAg was
obtained from a non-disclosed Hepatitis B vaccine
manufacturer. Ag85A was obtained from Lionex GmbH
(Braunschweig, Germany).
AlOH was purchased from Brenntag (Ballerup,
Denmark). Squalene-in-water emulsion SWE adjuvant
was prepared by the Vaccine Formulation Laboratory
(VFL) at the University of Lausanne, Epalinges,
Switzerland. SWE comprises a metabolizeable oil (squa-
lene 3.9% w/v), sorbitan trioleate (0.47% w/v), and poly-
oxyethylene (80) sorbitan monooleate (0.47% w/v)
dispersed in 10 mM citrate buffer at pH 6.5. QS21
saponin was prepared by the VFL following purification
of QuilA from Quillaja saponaria Molina (Brenntag,
Denmark) [19]. Liposomes (10 mg/mL dioleoylphospha-
tidylcholine and 2.5 mg/mL cholesterol) were prepared
at the VFL by dissolution of lipid and cholesterol in
chloroform, rotary evaporation and rehydration of the
lipid film with PBS and ultra-sonication followed by
sterile filtration, as previously described [20].
Preparation of formulations
The nine vaccine formulations were prepared under
sterile conditions, in a biological safety cabinet.
Table 1 gives an overview of how the formulations
were prepared. Of each formulation 500 μL was
prepared. The same amount of each antigen (containing
either 1 μg AMA1, 5 μg HBsAg or 10 μg Ag85A (final
antigen dose)) was used in different adjuvant formula-
tions. Per mouse 50 μL was injected at time of each
vaccination.
AlOH formulations were prepared by mixing 85 μL of
aluminium oxyhydroxide (containing 850 μg of elemen-
tary aluminium) with 165 μL of saline for injection (SFI)
followed by vortexing at high speed for 5 s. 250 μL of
antigen solution in SFI (containing either 10 μg AMA1,
50 μg HBsAg or 100 μg Ag85A) were mixed with AlOH
suspension, followed by vortexing at high speed for 5 s.
Adjuvant-only control was prepared by mixing 250 μL
of SFI with 250 μL of AlOH suspension (control group).
SWE formulations were prepared by mixing 250 μL of
SWE with 250 μL of antigen solution in PBS (containing
either 40 μg/mL AMA1, 200 μg/mL HBsAg or 400 μg/
mL Ag85A), followed by vortexing at high speed for 5 s.
Adjuvant-only control was prepared by mixing 250 μL
of PBS with 250 μL of SWE (control group).
QS21-Liposome formulations were prepared by adding
100 μL of QS21 solution in PBS (at 1 mg/mL) to 100 μL
of DOPC:Chol liposome suspension, followed by gentle
inversion and addition of 50 μL of PBS. After 5 min
QS21-Liposomes suspension was mixed with, 250 μL of
antigen solution in PBS (containing either 10 μg AMA1,
50 μg HBsAg or 100 μg Ag85A), followed by gentle
inversion. The adjuvant-only control (so no antigen) was
prepared by mixing 300 μL of PBS to 200 μL of QS21-
Liposome suspension (control group).
All formulations were injected within 2 h of preparation.
Characterization of formulations
Following preparation, a compatibility and stability study
of the nine different antigen-adjuvant combinations was
performed over a 24 h period of storage at room
temperature (RT), RT in the testing laboratory was
between 18 and 22 °C). The characterization methods
used were selected in accordance with each antigen and
adjuvant. AlOH formulations were first analyzed visually
for potential flocculation and centrifuged at 16,000 g for
2 min at RT. After centrifugation, 400 μL of supernatant
was quantified for non-adsorbed antigen, either by
ELISA (AMA1 and HBsAg formulations) or for Ag85A
Table 1 Preparation of the nine vaccine formulations (test group) and control groups
Formulations Test group Adjuvant-only control group
Adjuvant suspension Antigen solution
AlOH 85 μL AlOH + 165 μL SFI 10 μg AMA1 in 250 μL SFI 250 μL adjuvant suspension + 250 μL PBS
50 μg HBsAg in 250 μL SFI
100 μg Ag85A in 250 μL SFI
HBsAg 250 μL SWE 40 μg/mL AMA1 in 250 μL PBS 250 μL adjuvant suspension + 250 μL PBS
200 μg/mL HBsAg in 250 μL PBS
400 μg/mL Ag85A in 250 μL PBS
Ag85A 100 μL QS21 (1 mg/mL) + 100 μL
DOPC:Chol + 50 μL PBS
10 μg AMA1 in 250 μL PBS 200 μL adjuvant suspension + 300 μL PBS
50 μg HBsAg in 250 μL PBS
100 μg Ag85A in 250 μL PBS
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formulations by Micro BCA (Thermo Scientific, Wohlen,
Switzerland). The antigen adsorption rates were extrapo-
lated from the non-adsorbed antigen results.
SWE formulations and QS21-Liposome formulations
were characterized for particle size and/or zeta potential
using ZetaSizer® Nano ZS (Malvern, United Kingdom).
Samples were analyzed in triplicates at 20 °C. Antigen
integrity was analyzed by silver-stained SDS-PAGE
(Invitrogen, Lucerne, Switzerland).
Mouse immunization and blood sampling
All animal work was performed under the guidelines of
Biomedical Primate Research Centre (BPRC) which uses
protocols conforming to European animal welfare regu-
lations. The independent ethics committee at BPRC,
constituted according to Dutch law on animal experi-
ments, approved the study protocol (number DEC 658)
prior to start of the experiment. Immunization studies
were carried out in nine groups of nine female C57BL/6
mice (test groups) and three groups of three female
C57BL/6 mice (control groups).
Each animal was immunized (50 μL) intramuscularly
(i.m.) with AMA1, HBsAg or Ag85A antigens, combined
to one of the three adjuvants tested in this study. Immu-
nizations were performed under isoflurane inhalation
anesthesia. Control groups, one for each adjuvant, were
immunized with adjuvant only as described in paragraph
Preparation of formulations and Table 1. Control vac-
cines were administered at four weekly intervals (days 0,
28 and 56). Blood samples (100 μL) were taken at days 0
and 42. Animals were euthanized by cervical dislocation
under isoflurane at week 10 (day 70) when blood and
spleens were collected for analysis. The in vivo experi-
ment was performed only once. Seven mice were lost
due to experimental procedures (anesthesia) not related
to treatment. AMA1: AlOH/QS21 2 mice, HBsAg: SWE
1 mouse, Ag85A: QS21 2 mice, and SWE 2 mice.
ELISPOT
IFN-γ and IL-5 ELISPOT analyses were performed with
splenocytes obtained on day 70. Splenocytes were ob-
tained by passing mashed spleens through a 70 μm cell
strainer to a single cell suspension. Cells were washed
twice with RPMI and adjusted to a final volume of 5 mL
in culture medium (CM). CM contains RPMI (Gibco,
Invitrogen, Breda, The Netherlands) + 10% filtered FCS
(Gibco, Invitrogen, Breda, The Netherlands) + 1% Gluta-
max (Gibco, Invitrogen, Breda, The Netherlands) + 1%
Penicillin/Streptomycin (Gibco, Invitrogen, Breda, The
Netherlands). Counting of cells was done using Casy
Counter (Cell Counter and Analyser System - Model
TT, Schärfe System – Reutlingen, Germany). Cells were
plated at 5 × 105 cells per well and stimulated overnight
with 10 μg/mL antigen (AMA1, HBsAg or Ag85A).
PMA-Iono (1 μg/mL) was included as a positive control
(U-CyTech, Utrecht, The Netherlands). All samples were
tested in triplicate.
ELISPOT plates (MultiScreen HTS and Hi-flow, MilliPore,
Amsterdam, The Netherlands) were coated overnight with
anti-cytokine antibodies – IFN-γ and IL-5 (U-CyTech kit,
Utrecht, The Netherlands) according to manufacturers’
instructions. Following 24 h the stimulated splenocytes were
transferred into the coated ELISPOT plates and incubated
for 24 h at 37 °C in a 5% CO2 gassed incubator. ELISPOT
plates were developed according to manufacturers’ instruc-
tions using Streptavidin-HRP conjugate (U-CyTech, Utrecht,
The Netherlands). Spots were counted using AELVIS
(Elispot Reader, Hannover, Germany). ELISPOT counts are
presented as medium corrected counts per 106 cells (i.e.
counts obtained with medium only are subtracted from the
counts obtained with antigens). In the event medium stimu-
lated cells had higher counts than antigen stimulated cells 0
spot counts were arbitrarily assigned.
Enzyme-linked immunosorbent assay
HBsAg ELISA kit was obtained from Alpha Diagnostic
(San Antonio, USA). AMA1 ELISA (including 4G2 rat anti-
body, BG98, goat anti rabbit IgG conjugated to alkaline
phosphatase, para-nitro phenol phosphate and diethanola-
mine) was provided by BPRC and was used as described
previously [6]. ELISA was performed on serum samples in
96-well flat bottom Microlon titre plates (Greiner, Alphen
a/d Rijn, The Netherlands). Plates were coated with 1 μg/
mL antigen (AMA1 or HBsAg or Ag85A antigen (100 μL/
well)) at 4°C overnight. After blocking with 200 μL/well of
3% BSA (Sigma, Zwijndrecht, The Netherlands) in PBS-T,
day 0 – day 42 – day 70 serum samples were loaded to the
plates and incubated for 1 h at RT. Mouse day 0 samples
were tested at 1:100 and 1:500 for IgG-total and day 42 –
day 70 samples at different dilutions for the four IgG
subclasses: total IgG – IgG1 – IgG2b – IgG2c. All samples
were tested in duplicate.
For mouse ELISA a pool of day 70 sera samples was
used as a standard on every plate in a 2-fold serial dilu-
tion series. After sample incubation, plates were devel-
oped with 100 μL/well of 1:1000 diluted goat anti-mouse
antibody conjugated to horseradish peroxidase for all
four subclasses (Invitrogen, Breda, The Netherlands).
ELISA development was with 100 μL/well ready-to-use
TMB-substrate (Kem-en-Tec, Taastrup, Denmark) (for
15–20 min and stopped with 50 μL/well 2 mM H2SO4.
The optical density (OD) was read at 450 nm using
BioRad platereader (Model iMark – microplate reader,
Bio-Rad, Veenendaal, The Netherlands).
ODs were converted to arbitrary units (AUs) using a
four-parameter-logistic-fit (ADAMSEL, www.malariares
earch.eu), were 1 AU yields an OD of 1 over back-
ground. Thus the amount of AU of a sample is the
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reciprocal dilution at which an OD of 1 over background
will be achieved. A standard curve was included on
every plate.
Statistical analysis
All data are presented as medians with 25 and 75% percen-
tiles. Statistical significance was assessed by non-parametric
tests; a p-value < 0.05 is considered statistically significant.
Differences in antibody levels between the three adjuvant
groups were initially compared using the Kruskal-Wallis
(KW) test, where a p-value smaller than 0.05 indicates that
at least two of the three groups differ significantly. In the
event of a significant KW p-value, differences between the
three adjuvant groups were subsequently evaluated by
Mann-Whitney U (MW) tests. As three comparisons can
be made, the p-value at which significance is considered re-
quires adjustment by the Bonferroni method, i.e. p-values
smaller than 0.05/3 = 0.0167 were considered statistically
significant for the (secondary) Mann-Whitney comparisons.
Therefore the p-value was set at 0.0167 as significance level
for secondary comparisons.
Results
Survey and outcomes
In total 12 surveys were returned; six from research
groups in industry and six from research groups in
academia and/or governmental institutions. From the
completed questionnaires, it was evident than no two re-
search groups used similar methods for adjuvant com-
parison when down selecting candidates for their
research. Evaluation of adjuvant activity was mainly done
in mice, which was one of the few consensus points. A
plethora of mice strains, immunization schedules,
dosages and routes of immunization were listed. Based
on the questionnaire responses and an analysis of the
available literature it was clear that no ‘best practice’
evaluation method was prevalent, and that there was a
clear need for a method and protocol to be chosen as
the basis for a harmonized method.
As a first step, a harmonized animal model was
selected. The questionnaire revealed that two mouse
lines, BALB/c and C57BL/6 mice, were most commonly
used. As there are several issues associated with the
BALB/c mouse that could bias adjuvant comparisons,
such as IL-12 receptor insensitivity and sub-lines from
different suppliers, [9, 21] it was therefore decided to
use C57BL/6 mice.
Next, a route model was selected. The i.m. route of
immunization was chosen as the questionnaire responses
revealed a preference for this route, and it also is the most
frequently used route for human vaccine administration.
Nevertheless, the immunization volumes are 50 μL, which
is a small volume which can easily be injected in the quad-
riceps of the mice [22].
Finally, a schedule model was selected. Three injec-
tions were most commonly mentioned in the question-
naire results although there was no consensus on the
timing of these immunizations. Immunizations on days
0, 28 and 56 (which is similar to schedule of the World
Health Organization (WHO) Expanded Programme on
Immunisations (EPI)) was selected.
Characterization and stability of vaccine formulations
The different types of adjuvants used in the study have
specific characterization tools. For aluminium salts, high
importance is given to the antigen adsorption. It is usually
recommended that at least 80% of the vaccine antigens be
adsorbed on aluminium, [23]. In our study, all the super-
natants tested were below the level of antigen detection
(ELISA limit of quantification was 5 ng/mL for HBsAg
and 12.5 ng/mL for AMA1, and on mBCA™ limit of quan-
tification was 2 μg/mL) which has demonstrated a high
degree of antigen adsorption exceeding 95% for all the
antigen-aluminium formulations and remained constant
after 24 h at RT (Table 2). Besides, none of the AlOH
formulations showed any signs of flocculation suggesting
physico-chemical instability.
In the case of SWE emulsion and liposomes, the particle
size stability during storage is one of the criteria of import-
ance. Hydrodynamic diameter of SWE particles remained
constant at ~ 134 nm. Regarding QS21-Liposomes formula-
tions, the hydrodynamic diameter remained in the 110–
130 nm range. For all formulations, the integrity for all anti-
gens was confirmed in comparison to controls by SDS-PAGE
and/or ELISA (data not shown) and after 24 h storage.
ELISPOT / IFN-γ
No IFN-γ responses exceeding background were ob-
served in the control mice that received adjuvant only
Table 2 Characterization of formulations developed for the
study. Showing adsorption percentages after 2 h and 24 h for
AlOH formulations; Zeta potential and pH for SWE formulations;
particle size and pH for QS21-Liposome
AlOH SWE QS21-Liposomes
Antigen Time (h) Adsorption (%) Size (nm) pH Size (nm) pH
AMA1 2 > 99.9a 133.8 ± 1.2 6.27 130.8 ± 0.4 6.88
24 > 99.9a 133.9 ± 1.0 6.29 121.2 ± 1.6 6.98
HBsAg 2 > 99.9a 133.5 ± 1.5 6.26 134.0 ± 1.3 7.18
24 > 99.9a 133.6 ± 1.1 6.26 126.7 ± 0.1 7.14
Ag85A 2 > 98.0b 133.2 ± 1.1 6.48 139.6 ± 3.9 7.31
24 > 98.0b 134.3 ± 0.9 6.53 138.9 ± 1.2 7.37
Control 2 N/A 134.4 ± 2.3 6.50 132.1 ± 2.6 7.36
24 N/A 134.3 ± 1.0 6.51 111.7 ± 12.0 7.36
abased on ELISA results (limit of quantification was 12.5 ng/mL for AMA1 and
5 ng/mL for HBsAg)
bbased on mBCA™ (limit of quantification was 2 μg/mL)
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upon antigen stimulation (data not shown). For AMA1
the median number of IFN-γ spots showed an increasing
trend over the adjuvants/groups from 19 in the AlOH,
to 60 for the SWE and to 150 for the QS21-Liposomes
groups (Fig. 1), but none of the comparisons reached
statistical significance (p = 0.081, KW test). For HBsAg,
statistically significant differences were observed be-
tween the adjuvant groups (p < 0.00005, KW test), with
AlOH, SWE and QS21-Liposomes yielding medians of 0,
49 and 286 spots, respectively (Fig. 1) and all adjuvant
comparisons reached statistical significance (all p <
0.001, MW test). For Ag85A, statistically significant
differences were observed between the adjuvant groups
(p = 0.00012, KW test); the AlOH and SWE groups did
not show IFN-γ responses exceeding background values
(median count 0), whereas all animals in the QS21-
Liposomes group showed responses exceeding back-
ground and as a group had a median count of 120 spots
(p = 0.0001 KW test and p < 0.002 for comparisons of
QS21-Liposomes with AlOH or SWE MW test) (Fig. 1).
ELISPOT - Il-5
No IL-5 responses exceeding background were observed
in the control mice that received adjuvant only upon
antigen stimulation (data not shown). For AMA1 the
median number of IL-5 spots was 69, 150 and 92 for
AlOH, SWE and QS21-Liposomes respectively, this,
however, failed to reach statistical significance (p = 0.064,
KW test) (Fig. 2). For HBsAg statistically significant
differences were observed in the number of IL-5 spots,
with median spot counts of 24, 252 and 334, for AlOH,
SWE and QS21-Liposomes, respectively (p < 0.00005,
KW test and all between groups comparisons p < 0.011,
MW test) (Fig. 2). For HBsAg, the number of IL-5 spots
was significantly higher in the QS21-Liposomes group as
compared to the AlOH group (all p < 0.001, MW test)
(Fig. 2). The number of IL-5 spots tended to be higher
in the QS21-Liposomes group as compared to the
SWE-group, but this did not reach statistical significance
(p = 0.019, MW test). For antigen 85A both AlOH and
SWE failed to induce significant IL-5 responses, with
only one animal in the SWE group clearly responding.
By contrast, all animals in the QS21-Liposomes group
had a detectable IL-5 response with a median count of
180 spots (Fig. 2).
Antibody levels at baseline
Pre-vaccination total IgG serum titres were determined
in day 0 serum samples. All animals were negative for
total IgG to the antigen under investigation (data not
shown) and no significant differences were observed be-
tween the treatment groups for each antigen (p = 0.4573
for AMA1; p = 0.1893 for HBsAg and p = 0.3393 for
Ag85A, KW test).
Total IgG
At day 70 median IgG titres to AMA1 showed an
increasing trend over the adjuvant groups, with AlOH
yielding lowest, SWE intermediate and QS21-Liposomes
yielding highest responses (p = 0.004, KW test), although
non responders were also observed. Day 70 titres were
significantly higher in the QS21-Liposomes group as
compared to the AlOH and SWE groups (p = 0.0047 and
0.0111, respectively, MW test) (Fig. 3). Day 70 median
Fig. 1 IFN-γ spots per 106 spleen cells plotted for the three antigens with the three adjuvants. Boxes indicate quartile ranges (bottom and top)
and medians (middle). Same symbol within each treatment group refers to the same animal throughout all graphs
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IgG titres to HBsAg showed an increasing trend over
the adjuvant groups, with AlOH yielding lowest, SWE
intermediate and QS21-Liposomes yielding highest re-
sponses (p < 0.0001, KW test). Day 70 titres were signifi-
cantly higher in the QS21-Liposomes group as
compared to the AlOH and SWE groups (p < 0.0001 and
< 0.001, respectively, MW test) (Fig. 3). At day 70 no
statistically significant difference were observed in IgG
titres to Ag85A for the three adjuvant groups (p =
0.0818, KW test) (Fig. 3).
IgG1
At day 70 median IgG1 titres to AMA1 showed an
increasing trend over the adjuvant groups, with AlOH
yielding lowest, SWE intermediate and QS21-Liposomes
yielding highest responses (p = 0.004, KW test). Day 70
IgG1 titres differed significantly for the AlOH and
QS21-Liposomes groups (p = 0.0047, KW test) (Fig. 4).
Day 70 median IgG titres to HBsAg showed an increasing
trend over the adjuvant groups, with AlOH yielding
lowest, SWE intermediate and QS21-Liposomes yielding
highest responses (p = 0.0007, KW test). Day 70 titres were
significantly higher in the SWE and QS21-Liposomes
groups as compared to the AlOH group (p = 0.0055 and
0.0008, respectively, MW test) (Fig. 4). At day 70 statisti-
cally significant differences were observed in IgG1 titres to
Ag85A for the three adjuvant groups (p = 0.0038, KW
test). IgG1 titres were higher in the SWE group as
Fig. 2 IL-5 spots per 106 spleen cells plotted for the three antigens with the three adjuvants. Boxes indicate quartile ranges (bottom and top) and
medians (middle). Same symbol within each treatment group refers to the same animal throughout all graphs
Fig. 3 IgGt Median number of total IgG titres in AU/mL shown for the three antigens with the three adjuvants. Same symbol within each treatment
group refers to the same animal throughout all graphs
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compared to the AlOH group (p = 0.0311, MW test), but
this was not statistically significant after correction for
multiple tests. Day 70 IgG1 titres were highest in the
QS21-Liposomes group and this was significantly higher
as compared to the AlOH group (p = 0.0052, MW test),
but failed to reach significance for the comparison
with the SWE group after correction for multiple
tests (p = 0.0175, MW test) (Fig. 4).
IgG2b
At day 70 median IgG titres to AMA1 showed an increas-
ing trend over the adjuvant groups, with AlOH yielding
lowest, SWE intermediate and QS21-Liposomes yielding
highest responses (p = 0.0002, KW test). Day 70 titres were
significantly higher in the SWE and QS21-Liposomes
groups as compared to the AlOH group (p = 0.0060 and
0.0009, respectively, MW test) and QS21-Liposomes
group compared to SWE group (p = 0.0025) (Fig. 5). Day
70 median IgG2b titres to HBsAg showed an increasing
trend over the adjuvant groups, with AlOH yielding low-
est, SWE intermediate and QS21-Liposomes yielding
highest responses (p = 0.0001, KW test). Day 70 titres were
significantly higher in the SWE and QS21-Liposomes
groups as compared to the AlOH group (Fig. 5, p = 0.0060
and 0.0002, respectively, MW test) and QS21-Liposomes
group compared to SWE group (p = 0.0024) (Fig. 5). At
day 70 statistically significant differences were observed in
IgG2b titres to Ag85A for the three adjuvant groups
(Fig. 5, p = 0.0004, KW test). IgG2b titres were higher
in the QS21-Liposomes group as compared to the AlOH
group and higher in the SWE group compared to the
AlOH group (p = 0.0009 and p = 0.0040, respectively, MW
test), these results were statistically significant. However
the QS21-Liposomes group IgG2b titres compared to the
SWE group failed to reach statistical significance after
correction for multiple tests (Fig. 5, p = 0.0530, MW test).
IgG2c
At day 70 median IgG2c titres to AMA1 showed an
increasing trend over the adjuvant groups, with AlOH
yielding lowest, SWE intermediate and QS21-Liposomes
yielding highest responses (Fig. 6, p = 0.0072, KW test).
Day 70 titres were significantly higher in the QS21-
Liposomes group as compared to the AlOH and SWE
groups (p = 0.0082 and 0.0080, respectively, MW test)
(Fig. 6). At day 70 median IgG2c titres to HBsAg showed
an increasing trend over the adjuvant groups, with
AlOH yielding lowest, SWE intermediate and QS21-
Liposomes yielding highest responses (Fig. 6, p = 0.0000,
KW test). Day 70 titres were significantly higher in the
SWE and the QS21-Liposomes groups as compared to
the AlOH group (p = 0.0008 and 0.0003, respectively,
MW test) and QS21-Liposomes group compared to
SWE group (Fig. 6, p = 0.0003). At day 70 statistically
significant differences were observed in IgG2c titres to
Ag85A for the three adjuvant groups (Fig. 6, p = 0.0008,
KW test). IgG2c titres were higher in the QS21-
Liposomes group as compared to the AlOH group and
the SWE group (p = 0.0010 and 0.0006, respectively,
MW test), these results were statistically significant.
However, IgG2c titres of the SWE group compared to
the AlOH group failed to reach statistical significance
after correction for multiple tests (p = 0.7090, MW
test) (Fig. 6).
Overall QS21-Liposomes group yielded highest IgG
levels for all four IgG subtypes for all three antigens.
SWE group yielded in intermediate IgG levels for all
four IgG subtypes for all three antigens. AlOH group
yielded in low IgG levels for all four IgG subtypes
for AMA1 and HBsAg. For Ag85A the AlOH group
yielded in intermediate levels for IgG1, IgG2b, and
IgG2c. Total IgG levels for Ag85A were overall the
same.
Fig. 4 IgG1 Median number of IgG1 titres in AU/mL shown for the three antigens with the three adjuvants. Same symbol within each treatment
group refers to the same animal throughout all graphs
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Discussion
The findings described above have allowed the develop-
ment of a harmonized protocol which may prove useful
for the down selection of vaccine adjuvants during
preclinical studies. The data presented here is the foun-
dation of this harmonization, and compares the immune
responses observed in mice using three adjuvants formu-
lated with three model antigens. The data presented here
show that QS21 is an adjuvant capable of inducing IFN-
γ resulting in an IgG2 dominated IgG response, whereas
AlOH and SWE tend to induce an IL-5 dominated
cellular- and IgG1 dominated IgG response.
The immunological outcome of the in vivo study
revealed different immunological effects induced by the
different antigens combined with the same adjuvant.
The QS21-Liposome formulations (in combination with
all three antigens) induced a strong IFN-γ response,
which was confirmed by the level of IgG2b and IgG2c as
detected by ELISA. In contrast, no IFN-γ production
was detected when AlOH was combined with HBsAg
and Ag85A. This result was expected as AlOH is known
to be a weak inducer of IFN-γ type-responses [24]. The
SWE-adjuvanted group did not show any production of
IFN-γ when in combination with Ag85A, whereas some
IFN-γ responses were observed in combination with
AMA-1 and HBsAg, alongside an increase in the IgG2b
ELISA titers. The level of Th-2 cytokines, represented
here by IL-5, showed that the QS21-Liposome adjuvant
was a potent inducer of IL-5 when combined with all
the three antigens. However, when combined with
AlOH, only HBsAg and AMA1 immunization elicited
low numbers of spots whereas superior levels of IL-5
secretion were detected for these two antigens when
formulated with SWE. Moreover, production of IFN-γ is
known to induce B cells to bias the production of IgG2b
and IgG2c subclasses, whereas the production of IL-5
Fig. 5 IgG2b Median number of IgG2b titres in AU/mL shown for the three antigens with the three adjuvants. Same symbol within each treatment
group refers to the same animal throughout all graphs
Fig. 6 IgG2c Median number of IgG2c titres in AU/mL shown for the three antigens with the three adjuvants. Same symbol within each treatment
group refers to the same animal throughout all graphs
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biases B cells to produce more total IgG and IgG1 [25].
The data presented in this paper are in accordance with
this previous work.
The differences observed in the number of IFN-γ and
IL-5 spots in this study could potentially be a result of
the different concentrations used for the three antigens
(the selected concentrations were based on measurable
responses in previous studies) [6, 26, 27] or the different
T-cell re-stimulation conditions used. Therefore, from
these results, it is still difficult to compare the intensity of
immune responses obtained with the different antigens,
and it may be more beneficial to focus on the quality of
the immune response obtained. The tested adjuvants
yielded responses as were expected from previous studies.
However, the antigen often has some modulatory effect on
top of what is expected for a given adjuvant. The choice of
antigen can also influence the type of Th responses to
some degree, thus the three selected antigens may provide
a comprehensive coverage of various types of bias.
The proposed sets of harmonized protocols may be
downloaded at: http://www.pharvat.eu/achievements.
These are not intended to be in binding or optimal but
propose to bridge various studies evaluating adjuvants.
In the event routes or schedules other than those
proposed here are employed, the inclusion of a bridging
group (as per the proposed method) will facilitate
directly a comparison with other studies and thus con-
tribute to rational adjuvant selection. For instance, the
QS21-Liposome formulations which induced high levels
of immune responses with all antigens in all readouts
would be a good candidate to compare the influence of
varying experimental parameters.
Despite the efforts of harmonization, differences be-
tween experiments might still persist, and for example, ef-
forts to further harmonize the animal work (sampling
methods, animal handling, housing conditions, feeding,
chronobiology, etc); could help at homogenizing further
the final results of the different in vivo experiments. The
mouse model is an advantageous model for many aspects
(accessibility, cost, materials and tools available, etc.), but
it has also some important limitations when the data ob-
tained needs to be extrapolated to humans. The specificity
of the murine immune system, the size and physiology of
the animal, are fundamental issues when the effect of dif-
ferent adjuvants are compared as these criteria might im-
pact on their adjuvant mechanism. New approaches are
currently being developed in order to allow a better pre-
dictability of the response in humans like humanized mice
models [28, 29] which may allow increase the value of the
mouse model as a predictive tool of vaccine efficacy.
Conclusions
The main output of this study was to demonstrate that
standardizing protocols for adjuvant comparison is
feasible and may allow the harmonized testing of vaccine
adjuvants using reference materials. This is expected to
facilitate direct comparison of studies performed with
novel antigen-adjuvant combinations, and to contrib-
ute to more rationale adjuvant selection for vaccine
researchers and developers.
The data presented here can be used as guidance and
reference when designing adjuvant comparisons, and as
potential tool for the rational selection of adjuvants for
further development of experimental vaccines. Adjuvant
developers are encouraged to follow this harmonization
initiative or other initiatives [30]. Obviously, alternative
administration schedules, other routes of immunization
and other volumes of administration are possible. The
protocols can be extended to other adjuvants and other
antigens, but it remains essential that all antigen/adjuvant
and control formulations are tested under exactly the
same conditions and compared to results obtained with
the original harmonized protocol. It should also be noted
that the reference formulations are not suited to all routes
of administration, for example the intranasal route.
The antigens AMA1 and Ag85A selected in this study can
respectively be obtained through BPRC (Rijswijk, The
Netherlands) and Lionex GmbH (Braunschweig, Germany)
upon request. The ELISA reference sera can be obtained
from BPRC upon request. The adjuvants selected in this
study can be obtained through the Vaccine Formulation La-
boratory (University of Lausanne, Switzerland) upon request.
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